Evan Yu presents OMAHA-003, testing opevesostat, a CYP11A1 antagonist targeting one step earlier than abiraterone in steroid biosynthesis. The drug eliminates mineralocorticoids and cortisol alongside ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Tian Zhang outlines management strategies for patients progressing from metastatic hormone-sensitive to castration-resistant prostate cancer with upfront expectation-setting discussions. Dr. Zhang ...

Kevin Shee analyzes Decipher® GRID whole-transcriptome data in 500 active surveillance patients from UCSF. Cox proportional regression identified Long and Yu signatures predicting upgrade risk beyond ...

(UroToday.com) The 2026 GU ASCO annual meeting featured an innovations in kidney cancer in 2026 session and a presentation by Dr. Michael Hofman discussing emerging tools in imaging in renal cell ...

(UroToday.com) The 2025 SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Benjamin Garmezy discussing a phase 1 trial of mevrometostat (PF-06821497), a potent and ...

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...

Barcelona, Spain (UroToday.com) Taxanes (docetaxel, cabazitaxel) and androgen receptor-targeted therapies (ARTs; abiraterone, enzalutamide) are the standard of care in metastatic castration resistant ...

(UroToday.com) The 2024 American Society of Clinical Oncology (ASCO) annual meeting featured a session on prostate cancer, and a presentation by Dr. Michael Morris discussing a phase 1 study of ...

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13 th and 16 th, 2024 was host to a session on future therapy targets ...